Clinical Trials Logo

Acute Ischemic Stroke clinical trials

View clinical trials related to Acute Ischemic Stroke.

Filter by:

NCT ID: NCT00507806 Terminated - Clinical trials for Acute Ischemic Stroke

Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke

Start date: March 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The study is designed to examine the safety, tolerability, and activity of a combination of microbubbles (perflutren lipid microsphere [Definity®]) and continuous monitoring with 2 MHz transcranial Doppler ultrasound (TCD) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

NCT ID: NCT00504842 Terminated - Clinical trials for Acute Ischemic Stroke

Transcranial Ultrasound in Clinical SONothrombolysis

TUCSON
Start date: December 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

NCT ID: NCT00499902 Terminated - Clinical trials for Acute Ischemic Stroke

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.

NCT ID: NCT00222040 Terminated - Clinical trials for Acute Ischemic Stroke

Microbubbles and Ultrasound in Stroke Trial: MUST Study

Start date: June 2004
Phase: Phase 2
Study type: Interventional

To determine whether transcranial 2-MHz ultrasound combined with intravenous administration of microbubbles improves early recanalization in patients with acute ischemic stroke caused by middle cerebral artery (MCA) proximal occlusion treated with intravenous alteplase within 3 hours of symptom onset.